Tagged with Partnerships

Pharma Dr. Costas Piliounis discusses the importance of containing diabetes, the dampening effects budget ceilings have on companies’ performance and growth potential, as well as the positive influence which changes currently being implemented in the regulatory system will have on the industry moving forward.   Dr. Piliounis, to start off, you…

Pharma Prof. Manuela Battaglia (MB) and  Prof. Lorenzo Piemonti (LP) discuss the positioning of the Diabetes Research Institute (DRI) within the San Raffaele Scientific Institute and the global diabetes care community, their respective specialty areas and DRI’s commitment to translational medicine. The Diabetes Research Institute (DRI) is part of the International…

Pharma A leading consultant to IMS and Professor at Paris Dauphine University reveals how the French healthcare system is moving in two main strategic directions: increasingly relying on private funding through complementary health insurance, and breaking with the egalitarian principle that everybody should be reimbursed to the same extent irrespective of…

Pharma The Italian Medicines Agency, AIFA, sits at a crossroads. Its Director-General Prof. Luca Pani discusses the apparent contradiction in the agency’s mission at a time of constricting budgets and expensive medicines, how the agency’s role is evolving in response and in which ways the agency can collaborate with the industry.…

pharma The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France is and will always be important for any large pharma company, despite some particular challenges; and how France´s unique strength…

Pharma Bayer broke into the top ten multinationals in Egypt this year, after achieving a remarkable 110 percent growth over the last two years. General manager Hatem Safei discusses the developments that drove this strong expansion, and the overall potential he sees in the healthcare market going forward. What are the…

Pharma The managing director of MC Pharma Group, Henk Krebs illustrates how MC Pharma’s new operating structure enables the group to better service its clients, and also highlights the role of strategic partnerships in fueling the company’s growth ambitions both domestically and internationally. He also shares his insights on the South…

Pharma Muhammad Bodhania, Managing Director of Medreich South Africa discusses potential strategic implications of the recent acquisition of Medreich by Meiji and the importance of local partnerships for global success. Can you please give an overview of Medreich’s activites in South Africa, and how the Meiji acquisition has affected the company’s strategic outlook? The…

Pharma The managing director of Trinity Pharma, Gaby Simaan (Jnr) depicts Trinity’s evolution from a regulatory consultancy into a fully commercialized pharmaceutical company, and how their unique position in the private label space has allowed the company to significantly expand its pipeline of products and presence in the market. To begin,…

Pharma The managing director of Galderma South Africa, Jenny Wright reveals the importance of the dermatology sector within the country’s healthcare system, as well as the role Galderma is playing in bringing dermatological solutions to the market and raising awareness of skin diseases. She also illustrates the factors that have truly…

pharma Hans Schikan offers insights into the flourishing Dutch life sciences sector and the attractiveness of the local eco-system, citing a combination of the right science and the right attitude of people as the key formula for success. In 2014/2015, three Dutch biotechs (UniQure, ProQR, Galapagos) went public on Nasdaq, and…

Pharma The CEO of IPASA reveals how over the last ten months the priority has been to reach out to different stakeholders, rebuilding trust with the department of health, with patients and physicians; why a National Health Insurance scheme should be established to act as a true merger between the public and private…